• 
• 
• 
• 

FDA News and Drug Updates

Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation

Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression

FDA News

Supportive Care

Psychosocial Issues in Patients with Cancer: It’s Time for Real-World Interventions

Corbin Davis

Medical Cannabis in Patients with Advanced Cancer: Challenges Remain

Corbin Davis

Key Considerations for Implementing a Scalp Cooling Program

Dia Byrne, MSN, RN, ACNS-BC, OCN

View All Supportive Care Articles

Lung Cancer

Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression

Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC

FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib

View All Lung Cancer Articles

Conference Correspondent

Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?

The Importance of Compassion: Perspective From a Lifelong Patient

Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer

Addressing the Second Victim Phenomenon

Humanizing Cancer Care: The Patient Perspective

View All Conference Correspondent Articles

Most Popular Articles

Bendamustine-Rituximab versus Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Conference Correspondent  - ASH 2019 Post Wrap-Up

ELEVATE TN: Results of a Phase 3 Study of Acalabrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Conference Correspondent  - ASH 2019 Post Wrap-Up

Three-Year Update of the Phase 2 ABT-199 (Venetoclax) and Ibrutinib in Mantle-Cell Lymphoma (AIM) Study

Conference Correspondent  - ASH 2019 Post Wrap-Up

Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer

Web Exclusives - FDA Updates, Urothelial Cancer